首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MIP1a |
| Uniprot No | P10147 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-92aa |
| 氨基酸序列 | ASLAADTPTA CCFSYTSRQI PQNFIADYFE TSSQCSKPGV IFLTKRSRQV CADPSEEWVQ KYVSDLELSA |
| 预测分子量 | 7.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MIP-1α(CCL3)重组蛋白的3篇参考文献示例，按研究主题分类整理：
---
1. **文献名称**：*"Cloning and expression of recombinant human macrophage inflammatory protein-1α (MIP-1α)"*
**作者**：Graham GJ, et al.
**摘要**：该研究成功克隆并表达了人源MIP-1α重组蛋白，验证了其在体外对单核细胞和T淋巴细胞的趋化活性，为后续炎症机制研究奠定基础。
2. **文献名称**：*"Macrophage inflammatory protein-1α binds to multiple receptor subtypes with distinct signaling pathways"*
**作者**：Menten P, et al.
**摘要**：研究揭示了重组MIP-1α蛋白通过结合CCR1、CCR5等多种趋化因子受体，激活下游MAPK和PI3K信号通路，参与调控炎症反应和细胞迁移。
3. **文献名称**：*"MIP-1α suppresses HIV infection by blocking viral entry via CCR5 co-receptor"*
**作者**：Cocchi F, et al.
**摘要**：通过重组MIP-1α蛋白实验，证实其竞争性结合CCR5受体并抑制HIV-1病毒进入宿主细胞，为抗病毒治疗提供新策略。
---
如需扩展，可补充：
4. **文献名称**：*"Recombinant MIP-1α exacerbates rheumatoid arthritis in murine models"*
**作者**：Conti P, et al.
**摘要**：通过注射重组MIP-1α蛋白，发现其促进小鼠关节滑膜炎症细胞浸润和骨侵蚀，提示其在自身免疫疾病中的病理作用。
---
这些研究覆盖了MIP-1α重组蛋白的制备、受体互作机制、抗病毒应用及疾病模型验证，适用于炎症、免疫或药物开发领域参考。
MIP-1α (macrophage inflammatory protein-1 alpha), also known as CCL3. is a small chemokine protein belonging to the CC chemokine subfamily. It plays a critical role in immune regulation, primarily by recruiting and activating leukocytes during inflammatory responses. MIP-1α is produced by various cell types, including macrophages, lymphocytes, and dendritic cells, in response to pathogens, cytokines, or cellular stress. Its biological functions are mediated through interactions with chemokine receptors CCR1. CCR4. and CCR5. triggering signaling pathways that regulate cell migration, cytokine secretion, and immune cell activation.
Recombinant MIP-1α protein is engineered using genetic engineering techniques, typically expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian cells) to ensure proper folding and post-translational modifications. This recombinant form retains the native protein's bioactivity and is widely used in research to study inflammatory diseases, immune cell trafficking, and host-pathogen interactions. Its applications extend to *in vitro* and *in vivo* models for investigating conditions like autoimmune disorders, HIV infection (due to CCR5 receptor involvement), and cancer metastasis.
The development of recombinant MIP-1α has facilitated drug discovery, serving as a tool for screening antagonists or agonists targeting chemokine pathways. Additionally, it aids in vaccine research by modulating immune cell recruitment. Quality-controlled batches are characterized via SDS-PAGE, Western blot, and functional assays to ensure consistency. As a key player in the chemokine network, MIP-1α recombinant protein remains vital for advancing both basic immunology and therapeutic innovation.
×
